Loading...

STRO SUTRO BIOPHARMA INC Management Changes 8-K Filing

STR

STR

SUTRO BIOPHARMA INC

(STRO)

2025 8-K

Financial Results

Agreement Termination

Stock Offering Announcement

Regained Nasdaq Compliance

Stock Split Approved

Financial Results Released

Restructuring Plan

Financial Statements

Delisting due to Non-Compli...

Financial Statements

Board Departure

Management Changes

Financial Results

Financial Results

Director Appointment

Annual Meeting of Stockholders

Financial Results Announcement

Agreement for Stock Offering

Exclusive License Agreement...

Financial Results Announcement

Open Market Sale Agreement

Financial Disclosure

Agreement with Vaxcyte

Appointment of President an...

Financial Results Announcement

Agreement with Vaxcyte, Inc.

Financial Results Announcement

Sale of Royalty Interest

Termination of Collaboratio...

Financial Results Announcement

Resignation of Dr. Trevor H...

Resignation and Appointment

Financial Results Announcement

Amended and Restated Bylaws...

Presentation and Update

External Links:

On March 13, 2025, Sutro Biopharma announced its financial results for 2024 and completed a strategic review prioritizing three preclinical programs, leading to a workforce reduction of about 50% and estimated costs of $40-$45 million. Additionally, CEO William J. Newell and other executives are transitioning out, with Jane Chung appointed as the new CEO.

AI Assistant

SUTRO BIOPHARMA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.